WELCOME TO The Biotechnology REPORT
Pure Care Inc
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Peptilogics | January 11, 2022
Peptilogics, a biotech company that engineers peptide therapeutics to radically improve the treatment landscape for patients with life-threatening diseases, announced that the U.S. Food and Drug Administration as accepted the company's Investigational New Drug Application for PLG0206 to treat periprosthetic joint infection allowing the Phase 1b study to proceed.
Peptilogics will evaluate the safety and efficacy of PLG0206 in a Phase 1b open-label, dose-escalating study i...
1upHealth | June 07, 2022
MediKarma, Inc, a global leader in an AI-based patient engagement, education and navigation platform, has selected 1upHealth, the market leader offering healthcare's most complete FHIR® data platform, as its interoperability partner to help patients request and acquire their medical records through FHIR-based APIs. Fast Healthcare Interoperability Resources (FHIR®) is the future of healthcare that brings together claims and clinical information in one common standard to drive innovat...
FierceBiotech | March 06, 2020
The Fred Hutchinson Cancer Research Center is making its Seattle-based staff work from home in light of the emergence of a cluster of coronavirus cases in the city. The precautionary action comes as biopharma companies are starting to pull back from face-to-face events to cut the risk of their employees catching the virus. As of Thursday, all of Fred Hutch’s Seattle-based employees, bar security and other staff that need to be on campus, are working remotely. Fred Hutch plans to keep the m...
CELL AND GENE THERAPY
Gamma Biosciences | October 13, 2022
Gamma Biosciences, a leading provider of tools and technologies for cell and gene therapy manufacturing, through their BioMagnetic Solutions business announced a strategic collaboration with Lonza. Under the multi-year agreement, BioMagnetic Solutions will supply its proprietary research and cGMP manufacturing grade FerroSelect™ reagents to Lonza for use in developing CAR-T and other immunotherapeutic products using Lonza's Cocoon® Platform.
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE